retatrutide type 1 diabetes ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial New Kind of Diabetes Drug

Their use in this population carries serious risk of medical decompensation, refeeding syndrome, electrolyte abnormality, and psychological relapse

Early data from Alzheimer's trials has generated genuine excitement, proposing that GLP-1 signaling may modulate the neuroinflammation that drives cognitive decline

if dietary patterns remain unchanged, weight loss and glycaemic benefits will be limited

Sesames mission has been the same since day one: to build a marketplace that makes high-quality, affordable care easily accessible to the millions of Americans who are priced out of the traditional US healthcare system